Iovance Biotherapeutics Inc

21 de ago. de 2026, 20:02 UTC

Iovance Biotherapeutics is lower in Friday's session, with no specific news identified. The broader market also remains down significantly since Thursday's close.

20 de ago. de 2026, 23:06 UTC

Iovance Biotherapeutics reached a 52-week high after UBS raised its target price to $7, noting strong second-quarter sales of $91 million.

19 de ago. de 2026, 23:16 UTC

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

18 de ago. de 2026, 23:06 UTC

Iovance Biotherapeutics shares were roughly flat in after-market hours. The broader market faced pressure from rising bond yields and increased oil prices.

17 de ago. de 2026, 19:36 UTC

Iovance Biotherapeutics reaches a new 52-week high above $7 amid positive results from the IOV-LUN-202 trial for metastatic NSCLC.

14 de ago. de 2026, 23:26 UTC

Iovance Biotherapeutics Inc. gains in after-market trading, reaching a 52-week high above $7 amid positive sentiment for IOV-LUN-202 and upcoming updates.

13 de ago. de 2026, 19:21 UTC

Iovance Biotherapeutics Inc shares are lower today, reaching a midday low after earlier gains. No specific news was identified to explain the decline.

12 de ago. de 2026, 19:16 UTC

Iovance Biotherapeutics Inc shares rise amid positive social media discussions and analyst projections of over $400 million in revenue this year.

11 de ago. de 2026, 23:46 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid volatility. No specific news was identified to explain the price movement.

10 de ago. de 2026, 23:56 UTC

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

7 de ago. de 2026, 20:03 UTC

Iovance Biotherapeutics rises as Barclays and Citizens raise price targets amid positive sentiment and high trading volume.

6 de ago. de 2026, 20:03 UTC

Iovance Biotherapeutics reported record Q2 revenue of $99.3 million, exceeding estimates. The stock is higher amid strong demand and FDA Fast Track Designation for SAR-201.

5 de ago. de 2026, 23:16 UTC

Iovance Biotherapeutics shares are higher in after-market trading, reflecting broader market strength amid falling crude oil prices and strong corporate earnings.

4 de ago. de 2026, 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3 de ago. de 2026, 19:51 UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31 de jul. de 2026, 23:41 UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30 de jul. de 2026, 23:51 UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29 de jul. de 2026, 15:16 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28 de jul. de 2026, 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27 de jul. de 2026, 19:36 UTC

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24 de jul. de 2026, 19:12 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22 de jul. de 2026, 23:11 UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

21 de jul. de 2026, 19:46 UTC

Iovance Biotherapeutics shares are higher amid positive social media sentiment and favorable earnings reports from peers, including General Motors and Novartis.

20 de jul. de 2026, 19:16 UTC

Iovance Biotherapeutics Inc shares are higher today, with significant trading volume reaching 23.48 million. The stock has fluctuated between 4.44 and 5.07 during the session.